Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO) had its target price cut by research analysts at Stifel Nicolaus from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 2.09% from the stock’s previous close.

Several other research firms also recently commented on BLCO. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Morgan Stanley lowered Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a research report on Monday, December 2nd. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Bausch + Lomb in a research report on Thursday, December 12th. Royal Bank of Canada raised their target price on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, October 22nd. Finally, Wells Fargo & Company lowered their price target on shares of Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.25.

Bausch + Lomb Stock Down 1.4 %

Shares of BLCO opened at $17.63 on Wednesday. Bausch + Lomb has a 1 year low of $13.16 and a 1 year high of $21.69. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The stock has a 50 day simple moving average of $18.33 and a two-hundred day simple moving average of $18.13. The firm has a market cap of $6.21 billion, a P/E ratio of -16.79, a P/E/G ratio of 2.17 and a beta of 0.47.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.16 by $0.01. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The firm’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.22 EPS. On average, analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bausch + Lomb

A number of institutional investors have recently bought and sold shares of the stock. River Road Asset Management LLC boosted its position in Bausch + Lomb by 4.4% during the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock valued at $38,974,000 after acquiring an additional 85,987 shares in the last quarter. King Street Capital Management L.P. bought a new stake in shares of Bausch + Lomb during the third quarter valued at approximately $14,122,000. Barclays PLC purchased a new stake in Bausch + Lomb in the third quarter worth $5,797,000. Point72 DIFC Ltd bought a new position in Bausch + Lomb in the third quarter worth $4,331,000. Finally, Marshall Wace LLP purchased a new position in Bausch + Lomb during the second quarter valued at $1,911,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.